Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | May 21, 2026 | May 26, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Patient Officer | February 15, 2019 | March 06, 2019 |
| Lunai Bioworks Inc.RENB · Entity 7981 | Director | June 25, 2024 | June 27, 2024 |
| NOVAVAX INCNVAX · Entity 4632 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.69 · Expires 2036-05-21 | Direct | 12,500 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 12,500 · Balance 12,500 F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.
GILEAD SCIENCES, INC.
Report date February 15, 2019 · Filed March 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,046 |
Reported balance
After 2019-02-15 transaction · row 1
1 source rowRow 1 · 2019-02-15 · Grant · Acquired 330 · Balance 58,046 F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.01 · Expires 2029-03-01 | Direct | 9,640 |
Reported balance
After 2019-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-01 · Grant · Acquired 9,640 · Balance 9,640 F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 15,530 |
Reported balance
After 2019-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-01 · Grant · Acquired 1,890 · Balance 15,530 F3: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
F3: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F4: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested.
Lunai Bioworks Inc.
Report date June 25, 2024 · Filed June 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase shares of common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2034-06-25 | Direct | 48,137 |
Reported balance
After 2024-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-25 · Grant · Acquired 48,137 · Balance 48,137 |
NOVAVAX INC
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,685 |
Reported balance
After 2026-06-20 transaction · row 1
1 source rowRow 1 · 2026-06-20 · Exercise / conversion · Acquired 18,880 · Balance 47,685 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.13 · Expires 2036-06-18 | Direct | 21,270 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 21,270 · Balance 21,270 F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,180 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 14,180 · Balance 14,180 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-20 · Exercise / conversion · Disposed 18,880 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2009 Filed May 4, 2009 21:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,000 | $8.94 | $26,827.50 |
DisclosureSEC source: 0001179110-09-007108 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2009 Filed Apr 3, 2009 17:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001179110-09-006137 · edgar.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,580 Underlying: Common Stock · 3,000 shares Expires 2013-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 29, 2004, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 29, 2008. Read SEC document |
| April 01, 2009 Filed Apr 3, 2009 17:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $45.00 | $225,000.00 |
DisclosureSEC source: 0001179110-09-006137 · edgar.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,993 Read SEC document |
| April 01, 2009 Filed Apr 3, 2009 17:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,000 | $44.50 | $133,485.90 |
DisclosureSEC source: 0001179110-09-006137 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,993 F1 · price: Sale prices reported for the transactions reported here range from $44.48 to $44.50. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 01, 2009 Filed Apr 3, 2009 17:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,000 | $8.94 | $26,827.50 |
DisclosureSEC source: 0001179110-09-006137 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2009 Filed Mar 16, 2009 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 2,413 | $44.04 | $106,268.52 |
DisclosureSEC source: 0001179110-09-005163 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,993 Read SEC document |
| March 12, 2009 Filed Mar 16, 2009 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 5,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-09-005163 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,406 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on March 12, 2009. Read SEC document |
| March 03, 2009 Filed Mar 5, 2009 18:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $45.00 | $225,000.00 |
DisclosureSEC source: 0001179110-09-004297 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,696 Read SEC document |
| March 02, 2009 Filed Mar 4, 2009 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001179110-09-004056 · edgar.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,580 Underlying: Common Stock · 3,000 shares Expires 2013-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 29, 2004, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested January 29, 2008. Read SEC document |
| March 02, 2009 Filed Mar 4, 2009 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Disposition to issuerCommon Stock | 3,000 | $44.13 | $132,392.10 |
DisclosureSEC source: 0001179110-09-004056 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,696 Read SEC document |
| March 02, 2009 Filed Mar 4, 2009 00:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,000 | $8.94 | $26,827.50 |
DisclosureSEC source: 0001179110-09-004056 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2009 Filed Feb 6, 2009 00:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,300 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001179110-09-002141 · edgar.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,580 Underlying: Common Stock · 2,300 shares Expires 2013-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 29, 2004, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 29, 2008. Read SEC document |
| February 03, 2009 Filed Feb 6, 2009 00:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 2,300 | $52.01 | $119,623.00 |
DisclosureSEC source: 0001179110-09-002141 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,696 Read SEC document |
| February 03, 2009 Filed Feb 6, 2009 00:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,300 | $8.94 | $20,567.75 |
DisclosureSEC source: 0001179110-09-002141 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2009 Filed Feb 4, 2009 02:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,636 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001179110-09-001967 · edgar.xml · derivative · entry 10 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,880 Underlying: Common Stock · 4,636 shares Expires 2013-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 29, 2004, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 29, 2008. Read SEC document |
| February 02, 2009 Filed Feb 4, 2009 02:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 564 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001179110-09-001967 · edgar.xml · derivative · entry 9 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880 Underlying: Common Stock · 564 shares Expires 2011-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on October 25, 2002, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on October 25, 2006. Read SEC document |
| February 02, 2009 Filed Feb 4, 2009 02:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,200 | $50.94 | $264,902.56 |
DisclosureSEC source: 0001179110-09-001967 · edgar.xml · nonDerivative · entry 7 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,696 F5 · price: Sale prices reported for the transactions reported here range from $50.62 to $52.01. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 02, 2009 Filed Feb 4, 2009 02:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $50.56 | $252,803.00 |
DisclosureSEC source: 0001179110-09-001967 · edgar.xml · nonDerivative · entry 6 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,896 F4 · price: Sale prices reported for the transactions reported here range from $50.51 to $50.65. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 02, 2009 Filed Feb 4, 2009 02:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 4,636 | $8.94 | $41,457.43 |
DisclosureSEC source: 0001179110-09-001967 · edgar.xml · nonDerivative · entry 5 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2009 Filed Feb 4, 2009 02:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 564 | $8.58 | $4,839.85 |
DisclosureSEC source: 0001179110-09-001967 · edgar.xml · nonDerivative · entry 4 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2009 Filed Feb 4, 2009 02:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001179110-09-001967 · edgar.xml · derivative · entry 8 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,444 Underlying: Common Stock · 4,500 shares Expires 2011-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on October 25, 2002, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on October 25, 2006. Read SEC document |
| January 30, 2009 Filed Feb 4, 2009 02:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,500 | $51.43 | $231,457.05 |
DisclosureSEC source: 0001179110-09-001967 · edgar.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,696 F2 · price: Sale prices reported for the transactions reported here range from $51.32 to $51.49. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| January 30, 2009 Filed Feb 4, 2009 02:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $51.21 | $256,041.50 |
DisclosureSEC source: 0001179110-09-001967 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,196 F1 · price: Sale prices reported for the transactions reported here range from $51.15 to $51.31. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| January 30, 2009 Filed Feb 4, 2009 02:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 4,500 | $8.58 | $38,615.85 |
DisclosureSEC source: 0001179110-09-001967 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2009 Filed Jan 24, 2009 02:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $47.20 | $0.00 |
DisclosureSEC source: 0001179110-09-001494 · edgar.xml · derivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2019-01-21 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 21, 2010 the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 21, 2014. Read SEC document |
| December 19, 2008 Filed Dec 24, 2008 01:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option · Derivative | 1,500 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001179110-08-021488 · edgar.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,516 Underlying: Common Stock · 1,500 shares Expires 2013-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 29, 2004, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 29, 2008. Read SEC document |
| December 19, 2008 Filed Dec 24, 2008 01:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,500 | $50.00 | $75,000.00 |
DisclosureSEC source: 0001179110-08-021488 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,696 Read SEC document |
| December 19, 2008 Filed Dec 24, 2008 01:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,500 | $8.94 | $13,413.75 |
DisclosureSEC source: 0001179110-08-021488 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2008 Filed Dec 9, 2008 23:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option · Derivative | 500 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001179110-08-020634 · edgar.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,016 Underlying: Common Stock · 500 shares Expires 2013-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 29, 2004, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 29, 2008. Read SEC document |
| December 05, 2008 Filed Dec 9, 2008 23:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $47.00 | $23,500.00 |
DisclosureSEC source: 0001179110-08-020634 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,696 Read SEC document |
| December 05, 2008 Filed Dec 9, 2008 23:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 500 | $8.94 | $4,471.25 |
DisclosureSEC source: 0001179110-08-020634 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2008 Filed Dec 5, 2008 20:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option · Derivative | 500 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001179110-08-020501 · edgar.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,516 Underlying: Common Stock · 500 shares Expires 2013-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 29, 2004, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 29, 2008. Read SEC document |
| December 03, 2008 Filed Dec 5, 2008 20:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $45.00 | $22,500.00 |
DisclosureSEC source: 0001179110-08-020501 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,696 Read SEC document |
| December 03, 2008 Filed Dec 5, 2008 20:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 500 | $8.94 | $4,471.25 |
DisclosureSEC source: 0001179110-08-020501 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2008 Filed Dec 3, 2008 21:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option · Derivative | 5,500 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001179110-08-020333 · edgar.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,016 Underlying: Common Stock · 5,500 shares Expires 2013-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 29, 2004, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 29, 2008. Read SEC document |
| December 01, 2008 Filed Dec 3, 2008 21:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,500 | $43.49 | $239,214.80 |
DisclosureSEC source: 0001179110-08-020333 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,696 F1 · price: Sale prices reported for the transactions reported here range from $43.11 to $43.83. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 01, 2008 Filed Dec 3, 2008 21:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,500 | $8.94 | $49,183.75 |
DisclosureSEC source: 0001179110-08-020333 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2008 Filed Nov 5, 2008 18:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001179110-08-019005 · edgar.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,516 Underlying: Common Stock · 6,500 shares Expires 2013-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 29, 2004, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 29, 2008. Read SEC document |
| November 03, 2008 Filed Nov 5, 2008 18:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,500 | $47.41 | $213,345.00 |
DisclosureSEC source: 0001179110-08-019005 · edgar.xml · nonDerivative · entry 3 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,696 F2 · price: Sale prices reported for the transactions reported here range from $47.00 to $47.70. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 03, 2008 Filed Nov 5, 2008 18:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $45.99 | $91,980.00 |
DisclosureSEC source: 0001179110-08-019005 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,196 F1 · price: Sale prices reported for the transactions reported here range from $45.83 to $46.30. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 03, 2008 Filed Nov 5, 2008 18:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 6,500 | $8.94 | $58,126.25 |
DisclosureSEC source: 0001179110-08-019005 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2008 Filed Oct 17, 2008 18:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,136 | $0.00 Strike: $17.50 | $0.00 |
DisclosureSEC source: 0001179110-08-018287 · edgar.xml · derivative · entry 2 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,136 shares Expires 2013-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested 20% on July 30, 2004, the first anniversary date of the grant. The balance vested 5% every three months thereafter and was fully vested as of July 30, 2008. Read SEC document |
| October 15, 2008 Filed Oct 17, 2008 18:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,136 | $17.50 | $37,374.66 |
DisclosureSEC source: 0001179110-08-018287 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2008 Filed Oct 7, 2008 17:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001179110-08-017899 · edgar.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,016 Underlying: Common Stock · 500 shares Expires 2013-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested 20% on January 29, 2004, the first anniversary date of the grant. The balance vested 5% every three months thereafter and was fully vested as of January 29, 2008. Read SEC document |
| October 03, 2008 Filed Oct 7, 2008 17:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $47.00 | $23,500.00 |
DisclosureSEC source: 0001179110-08-017899 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,560 Read SEC document |
| October 03, 2008 Filed Oct 7, 2008 17:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 500 | $8.94 | $4,471.25 |
DisclosureSEC source: 0001179110-08-017899 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2008 Filed Oct 2, 2008 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001179110-08-017708 · edgar.xml · derivative · entry 3 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,516 Underlying: Common Stock · 6,000 shares Expires 2013-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested 20% on January 29, 2004, the first anniversary date of the grant. The balance vested 5% every three months thereafter and was fully vested as of January 29, 2008. Read SEC document |
| October 01, 2008 Filed Oct 2, 2008 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,000 | $45.31 | $271,860.00 |
DisclosureSEC source: 0001179110-08-017708 · edgar.xml · nonDerivative · entry 2 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,560 F1 · price: Sale prices reported for the transactions reported here range from $45.00 to $45.77. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 01, 2008 Filed Oct 2, 2008 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 6,000 | $8.94 | $53,655.00 |
DisclosureSEC source: 0001179110-08-017708 · edgar.xml · nonDerivative · entry 1 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2008 Filed Sep 4, 2008 18:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001179110-08-016400 · edgar.xml · derivative · entry 4 Alton Gregg H · CIK 0001334682 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,516 Underlying: Common Stock · 7,000 shares Expires 2013-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vested 20% on January 29, 2004, the first anniversary date of grant. The balance vested 5% every three months thereafter and was fully vested as of January 29, 2008. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.